
TMCI Stock Forecast & Price Target
TMCI Analyst Ratings
Bulls say
Treace Medical Concepts Inc. is experiencing growth in active surgeon users, which increased by 7.0% year-over-year to approximately 3,285, although utilization per surgeon has slightly declined. The company's strategic initiatives, including enhanced direct-to-consumer programs, improved physician education, and a bolstered sales force, are expected to contribute to modest revenue growth and potential margin improvements as average selling prices (ASPs) rise. Furthermore, the expansion of TMCI's product offerings beyond the Lapiplasty system aims to capture a larger market share in complementary foot and ankle procedures, positioning the company for long-term growth and a positive revenue outlook.
Bears say
Treace Medical Concepts Inc. is facing a negative financial outlook characterized by a projected revenue decline of approximately 10% year-over-year for the fourth quarter, with expected revenues of $61.8 million falling short of historical performance. The company's guidance for fiscal year 2025 has also been lowered to a range of $211-213 million, attributed to decreased volumes in elective bunion procedures and ongoing headwinds related to their Lapiplasty procedure. Additionally, with forecasts indicating negative year-over-year growth for 2026 before a modest recovery in 2027, the company's valuation multiple is expected to remain flat or decline further, reflecting a challenging market environment.
This aggregate rating is based on analysts' research of Treace Medical Concepts and is not a guaranteed prediction by Public.com or investment advice.
TMCI Analyst Forecast & Price Prediction
Start investing in TMCI
Order type
Buy in
Order amount
Est. shares
0 shares